<DOC>
	<DOCNO>NCT00138554</DOCNO>
	<brief_summary>Many people type 2 diabetes maintain target blood glucose level take single oral drug . This 28-week extension study assess safety effectiveness vildagliptin , unapproved drug , lower overall blood glucose level add pioglitazone people type 2 diabetes target blood glucose level pioglitazone rosiglitazone alone . The purpose extension study gather data long-term safety effectiveness vildagliptin people type 2 diabetes .</brief_summary>
	<brief_title>Extension Study Efficacy Safety Vildagliptin Combination With Pioglitazone Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Only patient successfully complete study CLAF237A2304 eligible Written inform consent Ability comply study requirement Premature discontinuation study CLAF237A2304 Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>